Literature DB >> 27695368

Progressive loss of vision caused by asymptomatic pituitary macroadenoma: role of OCT.

Víctor Manuel Asensio-Sánchez1, Javier Foncubierta1.   

Abstract

INTRODUCTION: Most pituitary adenomas are clinically inactive. In patients with long-standing compression of the optic chiasm, ganglion cells may undergo axonal degeneration. Spectral domain optical coherence tomography (SD-OCT) is able to identify retinal nerve fiber layer (RNFL) and ganglion cell loss in the retina. We present a case in which SD-OCT was used to diagnose an asymptomatic pituitary macroadenoma. CLINICAL CASE: A 48-year-old female presented with progressive vision loss in both eyes. SD-OCT identified atrophy of the ganglion cell and nerve layers, with preservation of outer layers bilaterally. Magnetic resonance imaging of the brain showed a pituitary macroadenoma. The pathological diagnosis was nonfunctioning adenoma. DISCUSSION: As macroadenomas enlarge, they can induce uncrossed axon loss, resulting in nasal field defects and reduced visual acuity. In these cases, there is atrophy of the nasal and temporal portions of the optic disc, thus occupying a horizontal band across the disc. SD-OCT is able to identify RNFL loss in eyes with band atrophy of the optic nerve, which correlates with visual field defects found in perimetry. SD-OCT is a useful tool to assess the structural and functional damage of ganglion cells. In our case the SD-OCT demonstrated a symmetrical loss of the RNFL and the ganglion cell layer in both eyes, indicating important optic nerve damage.

Entities:  

Keywords:  OCT; RNFL; adenoma; ganglion cell layer; pituitary

Year:  2016        PMID: 27695368      PMCID: PMC5033608          DOI: 10.2147/IMCRJ.S113339

Source DB:  PubMed          Journal:  Int Med Case Rep J        ISSN: 1179-142X


Introduction

Pituitary adenoma is the most common cause of the chiasmal syndrome.1 The tumor is classified based on size as microadenoma, smaller than 10 mm, or as macroadenoma when it exceeds 10 mm in diameter.2 Some tumors secrete one or more hormones in excess, so-called secretory pituitary adenomas, but most are clinically inactive.3 Classically, the nonsecretory tumors present with vision loss,4 whereas patients with secretory tumors are usually referred to ophthalmologists for evaluation due to hormonal imbalances that affect bodily functions.5 In patients with long-standing compression of the optic chiasm, ganglion cells may undergo axonal degeneration4. Such axonal loss can sometimes be observed in the optic disc and retina. Optical coherence tomography (OCT) is able to identify retinal nerve fiber layer (RNFL) and ganglion cell loss in retina.6,7 We present a case in which the OCT (3D OCT-2000 Spectral Domain OCT, Topcon Corporation, Tokyo, Japan) was used to diagnose an asymptomatic pituitary macroadenoma. The authors adhere to the International Standards developed in the 2nd Conference on Research Integrity in Singapore (2010), while performing this study. The patient agreed to have their case published, and all information presented is non-identifiable.8

Clinical case

A 48-year-old, Caucasian female presented with progressive vision loss in both eyes for several months. Her past ocular, medical, and family history was non-contributory with no fatigue, loss of libido, no mood change, and no weight change. On examination, best-corrected visual acuity was hand motion in the right eye and 2/3 in the left eye. The anterior segment and intraocular pressure examination were normal in each eye. The macula and peripheral retinal fluorescein angiography were normal in both eyes. Spectral domain optical coherence tomography (SD-OCT) demonstrated diffuse atrophy of the ganglion cell and nerve layers, with preservation of outer layers bilaterally (Figure 1 and Figure 2). Magnetic resonance imaging of the brain was performed and a pituitary macroadenoma with suprasellar extension was observed (Figure 3). Resection was performed and the pathological diagnosis was nonfunctioning adenoma. Despite the surgery, the vision did not improve.
Figure 1

Spectral domain coherence tomography identifies symmetric retinal nerve fiber layer and ganglion layer loss in the left eye (arrow).

Figure 2

Spectral domain coherence tomography identifies symmetric retinal nerve fiber layer and ganglion layer loss in the right eye (arrow).

Figure 3

Coronal view, post-contrast T1 brain magnetic resonance imaging, showing a pituitary macroadenoma with compression of the optic chiasm (arrow).

Discussion

Pituitary adenomas are common benign tumors of the pituitary gland that account for 12% of all intracranial tumors.9 People can develop pituitary adenomas at any age. Most pituitary adenomas are in the anterior lobe of the pituitary gland. Some adenomas secrete hormones in excess. Of the secretory tumors, the most common are prolactinomas.5 They may be relatively small when detected. The most common symptoms include headaches, menstrual changes in females, sexual dysfunction in males, vision problems, and behavioral changes.5 Diagnostic imaging may include a high-resolution, T1 weighted, gadolinium enhanced magnetic resonance imaging.10 Other secretory tumors may secrete corticotropin, growth hormone, gonadotropins, or thyroid-stimulating hormone.11 Adenomas remain confined to the pituitary gland, but when a pituitary adenoma is ≥10 mm it is called a macroadenoma. Macroadenomas can compress the rest of the pituitary gland and surrounding structures, such as the crossing retinal ganglion cell axons in the optic chiasm, resulting in bitemporal visual field loss.4 As the tumor enlarges, it has been shown to induce uncrossed axons loss, resulting in nasal field defects and reduced visual acuity. In these cases, there is atrophy of the nasal and temporal portions of the optic disc with relative sparing of the superior and inferior parts where the majority of temporal fibers enter. The optic atrophy occupies a horizontal band across the disc, called bowtie or band atrophy.12,13 OCT is a noninvasive technique that allows cross-sectional imaging of the retina and quantifies the thickness of the RNFL around the optic nerve head. A number of studies have demonstrated that OCT is able to identify RNFL loss in eyes with band atrophy of the optic nerve.6,7 The degree of RNFL thickness reduction has been shown to correlate with that of visual field defects using Goldmann perimetry4 and automated static perimetry.14,15 This fact gives OCT prognostic value regarding the visual outcome, as demonstrated in different studies.16,17 OCT is a useful tool to assess the structural and functional damage of ganglion cells, objectively and quantitatively.4 In our case the SD-OCT demonstrates a symmetrical loss of the RNFL and the ganglion cell layer in both eyes, indicating important optic nerve damage.

Conclusion

SD-OCT can help in the diagnosis of adenomas in equivocal situations in which there is only subtle optic nerve pallor in the setting of nonspecific visual complaints or visual field defects, or when patients are referred to screen for subclinical compressive optic neuropathies.
  15 in total

1.  Optical coherence tomography analysis of axonal loss in band atrophy of the optic nerve.

Authors:  M L R Monteiro; B C Leal; A A M Rosa; M D Bronstein
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

2.  Relationship between retinal nerve fiber layer and visual field sensitivity as measured by optical coherence tomography in chiasmal compression.

Authors:  Helen V Danesh-Meyer; Stuart C Carroll; Rod Foroozan; Peter J Savino; Jennifer Fan; Yannan Jiang; Stephen Vander Hoorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-11       Impact factor: 4.799

3.  Optical coherence tomography detects characteristic retinal nerve fiber layer thickness corresponding to band atrophy of the optic discs.

Authors:  Akiyasu Kanamori; Makoto Nakamura; Noriko Matsui; Azusa Nagai; Yoriko Nakanishi; Sentaro Kusuhara; Yuko Yamada; Akira Negi
Journal:  Ophthalmology       Date:  2004-12       Impact factor: 12.079

Review 4.  Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis.

Authors:  M Mercè Fernández-Balsells; Mohammad Hassan Murad; Amelia Barwise; Juan F Gallegos-Orozco; Anu Paul; Melanie A Lane; Julianna F Lampropulos; Inés Natividad; Lilisbeth Perestelo-Pérez; Paula G Ponce de León-Lovatón; Patricia J Erwin; Jantey Carey; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2011-04       Impact factor: 5.958

Review 5.  The pathophysiology of pituitary adenomas.

Authors:  Dorota Dworakowska; Ashley B Grossman
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-10       Impact factor: 4.690

Review 6.  The prevalence of pituitary adenomas: a systematic review.

Authors:  Shereen Ezzat; Sylvia L Asa; William T Couldwell; Charles E Barr; William E Dodge; Mary Lee Vance; Ian E McCutcheon
Journal:  Cancer       Date:  2004-08-01       Impact factor: 6.860

7.  Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population.

Authors:  W A Hall; M G Luciano; J L Doppman; N J Patronas; E H Oldfield
Journal:  Ann Intern Med       Date:  1994-05-15       Impact factor: 25.391

8.  The role of optical coherence tomography in the detection of pituitary adenoma.

Authors:  Charlotta Johansson; Bertil Lindblom
Journal:  Acta Ophthalmol       Date:  2008-09-03       Impact factor: 3.761

9.  Predicting visual outcome after treatment of pituitary adenomas with optical coherence tomography.

Authors:  Maud Jacob; Gérald Raverot; Emmanuel Jouanneau; Françoise Borson-Chazot; Gilles Perrin; Muriel Rabilloud; Caroline Tilikete; Martine Bernard; Alain Vighetto
Journal:  Am J Ophthalmol       Date:  2008-09-06       Impact factor: 5.258

Review 10.  Chiasmal syndromes.

Authors:  Rod Foroozan
Journal:  Curr Opin Ophthalmol       Date:  2003-12       Impact factor: 3.761

View more
  1 in total

1.  Predictive value of macular ganglion cell-inner plexiform layer thickness in visual field defect of pituitary adenoma patients: a case-control study.

Authors:  Li Xia; Jia Wenhui; Yang Xiaowen; Xie Wenfang; Zhang Wei; Hu Yanjun; Peng Xiaoyan
Journal:  Pituitary       Date:  2022-07-14       Impact factor: 3.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.